ArticleContact in context2026
Measuring Aztreonam Variations by Process Analytical Technology.
Article in Contact in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Aztreonam for injection (Fresenius Kabi) is a sterile, nonpyrogenic, sodium-free lyophilized, off-white to slightly yellow solid containing approximately 780 mg of arginine per gram of aztreonam, indicated for the treatment of specific infections caused by susceptible Gram-negative microorganisms. Ensuring the physical and chemical homogeneity of this lyophilized matrix is critical for consistent clinical efficacy; however, near-infrared (NIR) spectrometric screening coupled with high-dimensional principal component analysis (PCA) reveals complex, multidimensional inconsistencies within the commercially available product. Initial localized screening demonstrated significant intra-lot variability, with spectral data points forming a distinct toroidal pattern characteristic of cyclical oscillatory dynamics and an unstable mathematical average state. Extreme multidimensional outliers extending up to 5.6 standard deviations from the data centroid were observed diverging along multiple orthogonal trajectories, indicating that the intra-lot instability is driven by multiple independent physical and chemical mechanisms rather than a single processing failure. Expanding the evaluation to a comprehensive inter-lot analysis of 152 vials across 12 manufacturing lots confirmed that these inconsistencies persist at a systemic scale. The primary principal components divided the spectral library into two major, statistically distinct subpopulations, with asymmetric outlier distributions suggesting intermittent lapses in process control. Furthermore, projections in higher-order dimensions (PCs 7 through 9) isolated an entire manufacturing lot due to batch-level structural deviations possibly driven by trace moisture and aliphatic framework fluctuations. Nonparametric probability-density contour evaluations utilizing the FSOB algorithm and quantile-quantile (QQ) plots mathematically validated the presence of distinct subpopulations (r
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.